

| カタログ番号 | HV721026 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1-kappa |
| クローンID | NC762 |
| 生物学的活性 | NC762 (0.01-100 nM) binds to B7-H4 with an EC 50 of 1.12 nM in 624Mel.B7H4 cells and EC 50 of 0.976 nM in SKBR3 cells [2]. NC762 (0.1 ng/mL-100 ug/mL) binds to B7-H4 in human 293T cells but not mouse B7-H4 [2]. NC762 (0.1 pM-1000 nM) suggests increased binding to CD16a compared to V5.hlgG 1 [2]. NC762 (0.1-100 pM, 5 h) exhibits ADCC activity in 624Mel.B7H4 and SKBR3 cultured with effector Jurkat reporter cell line [2]. through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors [1]. |
| 発現システム | Mammalian cells |
| ターゲット | V-set domain-containing T-cell activation inhibitor 1, B7h.5, B7 homolog 4, B7-H4, T-cell costimulatory molecule B7x, B7H4, VTCN1, Protein B7S1, Immune costimulatory protein B7-H4 |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% purity as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | Q7Z7D3 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | NC762 |
| 背景 | V-set domain-containing T-cell activation inhibitor 1 (VTCN1/B7-H4) is a ~30 kDa protein. Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation. |
| 参考文献 | 1. Myint, Han, et al. "748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors." (2022). [HV721026] 2. Kristina Archer, et al. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies. Cancer Res 1 July 2021; 81 (13_Supplement): 3193. [HV721026] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SDS-PAGE for Research Grade Anti-Human VTCN1/B7-H4 (NC762).


+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский